☆ 4.6 Article

IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation

BMC CANCER (2022)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Yoshiaki Nakamura et al.

Summary: The study demonstrated that ctDNA genotyping can identify mCRC patients who benefit from pertuzumab plus trastuzumab treatment and monitor treatment response. The accuracy of ctDNA genotyping in identifying HER2-amplified mCRC patients was similar to tissue genotyping.

NATURE MEDICINE (2021)

Add to Collection

Article Dermatology

Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach

Kevin B. Kim et al.

Summary: Patients with melanomas carrying HR-DDR gene mutations show high tumor mutational burden and potentially benefit from checkpoint blockade treatment. Treatment with PARP inhibitors in these patients resulted in significant anti-tumor activity and affected apoptotic activity.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)

Add to Collection

Article Reproductive Biology

Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics

Alexandra Franz et al.

Summary: This study utilized mass spectrometry-based proteomics to characterize the response of HGSOC cells to PARP1 inhibitors, revealing significant proteomic changes in cancer cells treated with PARP1 inhibitors. The findings suggest potential protein targets for therapeutic inhibition in combination with PARP1 inhibitors, and highlight the importance of rational design of combination therapies in ovarian cancer.

JOURNAL OF OVARIAN RESEARCH (2021)

Add to Collection

Article Oncology

CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer

Hiroya Taniguchi et al.

Summary: Adaptive platform trials like CIRCULATE-Japan aim to evaluate the clinical benefits of ctDNA analysis and refine precision adjuvant therapy for resectable colorectal cancer. The trials include GALAXY, VEGA, and ALTAIR studies which focus on both de-escalation and escalation for ctDNA-negative and -positive patients respectively.

CANCER SCIENCE (2021)

Add to Collection

Review Oncology

SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors

Yoshiaki Nakamura et al.

Summary: Comprehensive genomic profiling plays an important role in detecting genomic biomarkers in advanced solid tumors, with the aim of matching patients with targeted therapy trials. The GI-SCREEN project has increased patient participation in clinical trials and led to the approval of new therapeutics. Utilizing clinicogenomic analyses, the SCRUM-Japan database has provided insights into the molecular mechanisms of advanced solid tumors.

CANCER SCIENCE (2021)

Add to Collection

Review Genetics & Heredity

Molecular profiling for precision cancer therapies

Eoghan R. Malone et al.

GENOME MEDICINE (2020)

Add to Collection

Article Oncology

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma

Matthew Kyle Labriola et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Medicine, General & Internal

Olaparib for Metastatic Castration-Resistant Prostate Cancer

J. de Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Pan-cancer landscape of homologous recombination deficiency

Luan Nguyen et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Oncology

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Aparna R. Parikh et al.

NATURE MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

A. Gonzalez-Martin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Jennifer K. Litton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?

Mathieu Cesaire et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Add to Collection

Article Medicine, General & Internal

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon-Koo Kang et al.

LANCET (2017)

Add to Collection

Article Multidisciplinary Sciences

Integrated genomic characterization of oesophageal carcinoma

Jihun Kim et al.

NATURE (2017)

Add to Collection

Article Medicine, General & Internal

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Mark Robson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

J. Bellmunt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

A. Gordon Robertson et al.

CELL (2017)

Add to Collection

Review Oncology

Targeting neoantigens to augment antitumour immunity

Mark Yarchoan et al.

NATURE REVIEWS CANCER (2017)

Add to Collection

Article Medicine, General & Internal

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

R. L. Ferris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

M. R. Mirza et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Multidisciplinary Sciences

Comprehensive molecular characterization of gastric adenocarcinoma

Adam J. Bass et al.

NATURE (2014)

Add to Collection

Article Genetics & Heredity

Integrated molecular analysis of clear-cell renal cell carcinoma

Yusuke Sato et al.

NATURE GENETICS (2013)

Add to Collection

Article Medicine, General & Internal

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

Jonathan Ledermann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.